Cargando…

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome

BACKGROUND: Gastrointestinal stromal tumour (GIST) is mainly initialised by receptor tyrosine kinase gene mutations. Although the tyrosine kinase inhibitor imatinib mesylate considerably improved the outcome of patients, imatinib resistance still remains a major therapeutic challenge in GIST therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akçakaya, P, Caramuta, S, Åhlen, J, Ghaderi, M, Berglund, E, Östman, A, Bränström, R, Larsson, C, Lui, W-O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260040/ https://www.ncbi.nlm.nih.gov/pubmed/25349971 http://dx.doi.org/10.1038/bjc.2014.548

Ejemplares similares

Imatinib Regulates miR-483-3p and Mitochondrial Respiratory Complexes in Gastrointestinal Stromal Tumors
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
por: Pulkka, Olli-Pekka, et al.
Publicado: (2017)

Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL
por: Rikhof, B, et al.
Publicado: (2008)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer
por: Xiong, S, et al.
Publicado: (2014)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
por: Widmer, N, et al.
Publicado: (2008)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
por: Wang, J, et al.
Publicado: (2012)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
por: Uziel, O, et al.
Publicado: (2005)

Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
por: Klawitter, J, et al.
Publicado: (2009)

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling
por: Weidenaar, A C, et al.
Publicado: (2011)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma
por: Caramuta, S, et al.
Publicado: (2013)

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
por: Vlahovic, G, et al.
Publicado: (2006)

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer
por: Hasegawa, S, et al.
Publicado: (2014)

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
por: Ryan, J, et al.
Publicado: (2012)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms
por: Amankwatia, E B, et al.
Publicado: (2015)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma
por: Trevisani, Francesco, et al.
Publicado: (2016)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
por: Liles, J S, et al.
Publicado: (2011)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
por: Lammers, T, et al.
Publicado: (2008)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas
por: Farace, P, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_isbd3p620ndbffmrci8kq4i494